Prokarium Launch Bladder Cancer Treatment Research

Located in the UK, Prokarium, a biotechnology firm, has trialled its experimental bacterial immunotherapy candidate, targeting US-based individuals with bladder cancer.    

This progression comes after the approval of their drug application from the US FDA at the end of 2023.  

The research objective is to analyse risks and clinical performance of the bladder administered treatment in on-muscle-invasive bladder cancer individuals.  

The firm’s Living Cures platform is crafted to update precision medicine through the development of customisable, ready-made treatments.  

Kristen Albright, the Chief Officer of Prokarium, stated, “This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.